<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00725231</url>
  </required_header>
  <id_info>
    <org_study_id>DSHNHL 2006-1B / ACT-2</org_study_id>
    <secondary_id>BMBF GFVT 01014715</secondary_id>
    <nct_id>NCT00725231</nct_id>
  </id_info>
  <brief_title>Immunotherapy in Peripheral T Cell Lymphoma - the Role of Alemtuzumab in Addition to Dose Dense CHOP</brief_title>
  <acronym>A-CHOP-14</acronym>
  <official_title>Phase III Study of CHOP-14 Plus or Minus Alemtuzumab in Peripheral T-cell Lymphoma of the Elderly</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Göttingen</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>German High-Grade Non-Hodgkin's Lymphoma Study Group</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Nordic Lymphoma Group</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Göttingen</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Peripheral T cell lymphomas comprise 10-15% of all malignant lymphomas. The prognosis is
      significantly worse than that of aggressive B cell lymphomas. The prospects of elderly
      patients are especially poor, with an estimated disease free survival of only 25% after three
      years. Previous phase II trials have demonstrated a significant activity of the monoclonal
      anti CD52 antibody alemtuzumab in primary and relapsed T cell lymphoma. The investigators
      thus propose to investigate the value of adjuvant alemtuzumab in combination with dose dense
      CHOP-14 in patients with previously untreated peripheral T cell lymphoma.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>February 2008</start_date>
  <completion_date type="Anticipated">March 2014</completion_date>
  <primary_completion_date type="Anticipated">March 2014</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Event free survival</measure>
    <time_frame>3 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Rate of complete and partial remissions</measure>
    <time_frame>4 months after inclusion</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>treatment related deaths</measure>
    <time_frame>time of occurence</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>@ 3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>protocol adherence</measure>
    <time_frame>4 months of treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>immune reconstitution after alemtuzumab CHOP</measure>
    <time_frame>3 years</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">274</enrollment>
  <condition>Peripheral T Cell Lymphoma, Unspecified</condition>
  <condition>Angioimmunoblastic Lymphadenopathy</condition>
  <condition>Extranodal NK/T-cell Lymphoma</condition>
  <arm_group>
    <arm_group_label>Arm A</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Chemotherapy with dose dense CHOP-14, 6 cycles</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Chemotherapy with dose dense CHOP-14, 6-cycles, together with 30mg Alemtuzumab s.c. for the first 4 cycles</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>alemtuzumab</intervention_name>
    <description>Addition of 30 mg Alemtuzumab by subcutaneous application for the first 4 cycles</description>
    <arm_group_label>Arm B</arm_group_label>
    <other_name>monoclonal anti CD52 antibody</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>chemotherapy</intervention_name>
    <description>dose dense chemotherapy with CHOP-14, 6 cycles, + G-CSF</description>
    <arm_group_label>Arm A</arm_group_label>
    <arm_group_label>Arm B</arm_group_label>
    <other_name>chemotherapy cylcophosphamide, hydroxyldaunorubicin</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  all risk groups of peripheral T cell lymphoma

          -  performance status ECOG 0-2

          -  written consent

          -  measurable disease

        Exclusion Criteria:

          -  stage I N without bulky disease

          -  already initiated treatment

          -  serious accompanying disorder or impaired organ function

          -  bone marrow involvement &gt;25%

          -  HIV positivity

          -  leukemic manifestation of lymphoma

          -  simultaneous participation in another trial

          -  platelets &lt; 100 000/ mm, leukocytes &lt; 2500 /mm
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>61 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Lorenz H Trümper, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Göttingen</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Lorenz H Trümper, MD</last_name>
    <phone>+49 551 398535</phone>
    <phone_ext>8535</phone_ext>
    <email>lorenz.truemper@med.uni-goettingen.de</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Gerald G Wulf, MD</last_name>
    <phone>+49 551 396303</phone>
    <phone_ext>6303</phone_ext>
    <email>gwulf@med.uni-goettingen.de</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University of Göttingen</name>
      <address>
        <city>Göttingen</city>
        <state>Lower Saxony</state>
        <zip>37099</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <link>
    <url>http://www.lymphome.de/Gruppen/DSHNHL/Protokolle/</url>
    <description>main site of German lymphoma trial groups</description>
  </link>
  <verification_date>May 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 25, 2008</study_first_submitted>
  <study_first_submitted_qc>July 25, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 30, 2008</study_first_posted>
  <last_update_submitted>May 4, 2012</last_update_submitted>
  <last_update_submitted_qc>May 4, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 7, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Göttingen</investigator_affiliation>
    <investigator_full_name>Prof. Dr. Lorenz Trümper</investigator_full_name>
    <investigator_title>Head of Departement of Haemtology and Oncology</investigator_title>
  </responsible_party>
  <keyword>T cell lymphoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Lymphoma, T-Cell</mesh_term>
    <mesh_term>Lymphoma, T-Cell, Peripheral</mesh_term>
    <mesh_term>Lymphoma, Extranodal NK-T-Cell</mesh_term>
    <mesh_term>Lymphadenopathy</mesh_term>
    <mesh_term>Immunoblastic Lymphadenopathy</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Alemtuzumab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

